Business
Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., April 20, 2026--Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Spruce B
About this update from Spruce Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1175,"height":380,"url":"https://media.zenfs.com/en/business-wire.com/2b0534555e7dd79e925382384913343c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QE7V0g1t.2N4glis26qLjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxMA--/https://media.zenfs.com/en/business-wire.com/2b0534555e7dd79e925382384913343c","width":960,"height":310},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/s28gHgeWtpqvVHCHGyiNiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNTA7aD03NjA-/https://media.zenfs.com/en/business-wire.com/2b0534555e7dd79e925382384913343c","width":1175,"height":380}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 20, 2026--(BUSINESS WIRE)--Spruce Biosciences, Inc. ("Spruce Biosciences") (NASDAQ: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that it has commenced an underwritten public offering of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Spruce Biosciences. In addition, Spruce Biosciences expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15% of the aggregate number of shares sold in the offering at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.","length":1043,"tagName":"p"},{"type":"text","content":"Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. are acting as joint book-running managers and Jones and Craig-Hallum are acting as co-managers for the proposed offering.","length":188,"tagName":"p"},{"type":"text","content":"The shares of common stock and pre-funded warrants are being offered by Spruce Biosciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (the "SEC") on October 29, 2025 and subsequently declared...